Ciltacabtagene Autoleucel out-of-Specification Manufacturing Outcomes Improve with Earlier Lines of Therapy

Key Points

• Improved manufacturing outcomes are associated with earlier lines of therapy for ciltacabtagene autoleucel.
• Key metrics demonstrate a significant reduction in out-of-specification rates when earlier therapies are administered.
• Analysis of manufacturing processes indicates that adjustments can lead to better performance metrics across therapy lines.
• May enable more effective use of ciltacabtagene autoleucel in treatment regimens, potentially enhancing patient outcomes.